Convertino, ConvertinoChurch, TimothyOlsen, GearyLiu, YangDoyle, EddieElcombe, CliffordBarnett, AnnaSamuel, LeslieMacPherson, IainEvans, Thomas2018-11-092018-11-092018-05-01Convertino, C, Church, T, Olsen, G, Liu, Y, Doyle, E, Elcombe, C, Barnett, A, Samuel, L, MacPherson, I & Evans, T 2018, 'Stochastic Pharmacokinetic/Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA)', Toxicological Sciences, vol. 163, no. 1, pp. 293-306. https://doi.org/10.1093/toxsci/kfy0351096-6080ORCID: /0000-0002-8402-8670/work/50559783http://hdl.handle.net/2164/11415This work was supported by the sponsor of this phase 1 clinical trial, CXR Biosciences (Dundee, UK). 3 M Company (St Paul, Minnesota) licensed a part of the database from CXR Biosciences for the purpose of the analyses presented herein.14998045engSDG 3 - Good Health and Well-beingAPFOphase 1 trialPK/PD modelingcholesterolPFOAthyroidR MedicinePharmacology, Toxicology and Pharmaceutics(all)RJournal article10.1093/toxsci/kfy0351631